Literature DB >> 30172963

Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion.

Cédric Carrié1, Rachel Legeron2, Laurent Petit3, Julien Ollivier4, Vincent Cottenceau5, Nicolas d'Houdain6, Philippe Boyer7, Mélanie Lafitte8, Fabien Xuereb9, François Sztark10, Dominique Breilh11, Matthieu Biais12.   

Abstract

PURPOSE: To determine whether augmented renal clearance (ARC) impacts negatively on piperacillin-tazobactam unbound concentrations in critically ill patients receiving 16 g/2 g/day administered continuously.
MATERIAL AND METHODS: Fifty nine critically ill patients without renal impairment underwent 24-h creatinine clearance (CrCL) measurement and therapeutic drug monitoring during the first three days of antimicrobial therapy by piperacillin-tazobactam. The main outcome was the rate of piperacillin underexposure, defined by at least one of three samples under 16 mg/L. Monte Carlo simulation was performed to predict the distribution of piperacillin concentrations for various CrCL and minimal inhibitory concentration (MIC) values.
RESULTS: The rate of piperacillin underexposure was 19%, significantly higher in ARC patients (0 vs. 31%, p = .003). A threshold of CrCL ≥ 170 mL/min had a sensitivity and specificity of 1 (95%CI: 0.79-1) and 0.69 (95%CI: 0.61-0.76) to predict piperacillin underexposure. In ARC patients, a 20 g/2.5 g/24 h PTZ dosing regimen was associated with the highest probability to reach the 16 mg/L empirical target, without risk of excessive dosing.
CONCLUSIONS: When targeting a theoretical MIC at the upper limit of the susceptibility range, the desirable target (100%fT>16) may not be achieved in patients with CrCL ≥ 170 mL/min receiving PTZ 16 g/2 g/day administered continuously.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Augmented renal clearance; Critical illness; Pharmacokinetics; Piperacillin – Tazobactam; Β-Lactams

Mesh:

Substances:

Year:  2018        PMID: 30172963     DOI: 10.1016/j.jcrc.2018.08.026

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  12 in total

Review 1.  Drug Dosing in Critically Ill Adult Patients with Augmented Renal Clearance.

Authors:  Fatma Hefny; Sukhvir Sambhi; Cassidy Morris; Janice Y Kung; Anna Stuart; Sherif Hanafy Mahmoud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-06-28       Impact factor: 2.569

2.  Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation.

Authors:  Cristina Sanches; Geisa C S Alves; Andras Farkas; Samuel Dutra da Silva; Whocely Victor de Castro; Farah Maria Drummond Chequer; Francisco Beraldi-Magalhães; Igor Rafael Dos Santos Magalhães; André de Oliveira Baldoni; Mark D Chatfield; Jeffrey Lipman; Jason A Roberts; Suzanne L Parker
Journal:  Antibiotics (Basel)       Date:  2022-03-24

3.  Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients.

Authors:  Joan Antoni Schoenenberger-Arnaiz; Faten Ahmad-Diaz; Mar Miralbes-Torner; Ana Aragones-Eroles; Manuel Cano-Marron; Mercedes Palomar-Martinez
Journal:  Eur J Hosp Pharm       Date:  2019-02-27

4.  Increased dosing regimens of piperacillin-tazobactam are needed to avoid subtherapeutic exposure in critically ill patients with augmented renal clearance.

Authors:  Thibaud Besnard; Cédric Carrié; Laurent Petit; Matthieu Biais
Journal:  Crit Care       Date:  2019-01-16       Impact factor: 9.097

5.  Increased β-Lactams dosing regimens improve clinical outcome in critically ill patients with augmented renal clearance treated for a first episode of hospital or ventilator-acquired pneumonia: a before and after study.

Authors:  Cédric Carrié; Grégoire Chadefaux; Noémie Sauvage; Hugues de Courson; Laurent Petit; Karine Nouette-Gaulain; Bruno Pereira; Matthieu Biais
Journal:  Crit Care       Date:  2019-11-27       Impact factor: 9.097

Review 6.  Prevalence and Risk Factors of Augmented Renal Clearance: A Systematic Review and Meta-Analysis.

Authors:  Fatma Hefny; Anna Stuart; Janice Y Kung; Sherif Hanafy Mahmoud
Journal:  Pharmaceutics       Date:  2022-02-19       Impact factor: 6.321

7.  Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?

Authors:  Helena Colom-Codina; Ariadna Padullés-Zamora; Erika Esteve-Pitarch; Víctor Daniel Gumucio-Sanguino; Sara Cobo-Sacristán; Evelyn Shaw; Kristel Maisterra-Santos; Joan Sabater-Riera; Xosé L Pérez-Fernandez; Raül Rigo-Bonnin; Fe Tubau-Quintano; Jordi Carratalà
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-06-15       Impact factor: 2.441

8.  Augmented Renal Clearance Following Traumatic Injury in Critically Ill Patients Requiring Nutrition Therapy.

Authors:  Roland N Dickerson; Christin N Crawford; Melissa K Tsiu; Cara E Bujanowski; Edward T Van Matre; Joseph M Swanson; Dina M Filiberto; Gayle Minard
Journal:  Nutrients       Date:  2021-05-15       Impact factor: 5.717

9.  Personalized Antibiotic Therapy for the Critically Ill: Implementation Strategies and Effects on Clinical Outcome of Piperacillin Therapeutic Drug Monitoring-A Descriptive Retrospective Analysis.

Authors:  Schrader Nikolas; Riese Thorsten; Kurlbaum Max; Meybohm Patrick; Kredel Markus; Surat Güzin; Scherf-Clavel Oliver; Strate Alexander; Pospiech Andreas; Hoppe Kerstin
Journal:  Antibiotics (Basel)       Date:  2021-11-26

10.  Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial.

Authors:  Stefan Hagel; Friedhelm Bach; Thorsten Brenner; Hendrik Bracht; Alexander Brinkmann; Thorsten Annecke; Andreas Hohn; Markus Weigand; Guido Michels; Stefan Kluge; Axel Nierhaus; Dominik Jarczak; Christina König; Dirk Weismann; Otto Frey; Dominic Witzke; Carsten Müller; Michael Bauer; Michael Kiehntopf; Sophie Neugebauer; Thomas Lehmann; Jason A Roberts; Mathias W Pletz
Journal:  Intensive Care Med       Date:  2022-02-01       Impact factor: 41.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.